ホーム / ニュース / サターラが James E. Cashman III を取締役会議長に任命

サターラが James E. Cashman III を取締役会議長に任命

High-tech CEO with decades of experience supports continued innovation and growth

プリンストン、ニュージャージー:2021 年 11 月 8 日 バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT)は、CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of 2021 年 12 月 1 日.  Jim succeeds Sherilyn McCoy, who is stepping down from the Board to focus on other professional commitments.

“It has been a privilege to serve as Chairman of Certara’s Board of Directors, and I am proud of the Company’s strong performance and accomplishments,” said Ms. McCoy. “Certara is well-positioned for continued success with an outstanding leadership team.”

“On behalf of the Board, I would like to thank Sheri for all of her contributions to Certara.  We wish her all the best in her endeavors,” said William F. Feehery, Ph.D., CEO of Certara. 

“I am excited to continue working with Jim as he assumes the role of Chairman.  His proven track record at Ansys and passion for simulation-driven product development will help advance Certara’s innovation and global expansion.”

James E. Cashman III has been a board member at Certara since 2018.  He served for 20 years in the CEO and Executive Chairman roles at ANSYS, Inc., the global leader of engineering simulation software. Under his leadership, Ansys grew from $50 million to over $1 billion in revenue and was one of the top five public technology companies in total shareholder returns. 

“I am honored to serve as Chairman of Certara’s Board.  I am inspired by Certara’s cutting-edge biosimulation technology and its impact on improving the drug development process and patient outcomes,” said James Cashman. “I look forward to working closely with the Board, William and the leadership team to create sustained value for all of Certara’s stakeholders.”


Certara(サターラ) について

サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。

【本件に関するお問合わせ先】

Investor Relations

David Deuchler
Gilmartin Group
ir@certara.com

Media

赤津笑美 emi.akatsu@certara.com
サターラ合同会社
daniel.yunger@kekstcnc.com

衣斐桃果
m-ebi@prap.co.jp
ariane.lovell@finnpartners.com

※英語または日本語でお問合せください

トップに戻る
Powered by Translations.com GlobalLink OneLink Software